Skip to main content

Zulresso Disease Interactions

There are 2 disease interactions with Zulresso (brexanolone).

Major

Brexanolone (applies to Zulresso) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The effect of end stage renal disease (ESRD, eGFR < 15 mL/minute/1.73 m2) on brexanolone pharmacokinetics is unknown, and its use should be avoided in these patients because of the potential accumulation of the solubilizing agent, betadex sulfobutyl ether sodium. No dosage adjustment is recommended in patients with mild (eGFR 60 to 89 mL/minute/1.73 m2), moderate (eGFR 30 to 59 mL/minute/1.73 m2) or severe (eGFR 15 to 29 mL/minute/1.73 m2) renal impairment.

References

  1. (2019) "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc.
Moderate

Brexanolone (applies to Zulresso) depression

Moderate Potential Hazard, Moderate plausibility.

Brexanolone is indicated for the treatment of postpartum depression. A placebo-controlled trial showed that patients with a previous diagnosis of major depressive disorder (MDD) had a higher incidence of suicidal thoughts and behaviors when treated with brexanolone. Consider changing the therapeutic regimen, including discontinuing brexanolone, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors.

References

  1. (2019) "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc.

Zulresso drug interactions

There are 272 drug interactions with Zulresso (brexanolone).

Zulresso alcohol/food interactions

There is 1 alcohol/food interaction with Zulresso (brexanolone).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer